Key Takeaways
- ClinicalTrials.gov lists the CuHeal study, NCT07437586, as a recruiting Phase 2 trial evaluating a GHK-Cu gel in standardized acute skin wounds.
- The study plans to enroll 60 healthy adults and compare two wounds within each participant: one assigned to the GHK-Cu formulation and one to its vehicle.
- The primary endpoint is time to complete re-epithelialization, assessed through blinded clinical review and standardized photography over 21 days.
- Scar quality, wound-area change, local symptoms, infection, tolerability, and adverse events are listed as secondary outcomes.
- No results are posted. Estimated primary completion is February 2027, so the trial cannot currently support an efficacy conclusion.
- Earlier cell, animal, mechanistic, and cosmetic literature supplies context, but it is not equivalent to a completed randomized wound-healing trial.
GHK-Cu entered a new evidence stage in 2026 with the registration of the CuHeal Phase 2 study. The recruiting trial uses a paired, vehicle-controlled wound model to ask whether wounds assigned to a GHK-Cu gel reach complete epithelial coverage sooner than comparison wounds in the same participants. Its design is informative, but its findings are still pending: the registry reports no results and lists February 2027 as the estimated primary-completion date.
Research boundary: This article explains a public trial record and prior laboratory literature. It is not medical advice and provides no dosing, route, administration, treatment, efficacy, or safety guidance. BioPharma compounds are for research and laboratory use only and are not intended for human or veterinary use.
What Is GHK-Cu?
GHK-Cu is a complex formed when the tripeptide glycyl-L-histidyl-L-lysine binds copper(II). GHK has been identified in human plasma and other biological fluids, while the copper complex has been studied in skin-remodeling, extracellular-matrix, inflammatory-signaling, and wound-model research.
The chemical identity matters. GHK, GHK-Cu, and a formulated GHK-Cu gel are related but not interchangeable experimental materials. Findings can also depend on concentration, vehicle, model, tissue, endpoint, and study duration. BioPharma’s GHK-Cu beginner’s guide covers the compound’s basic identity; this article focuses narrowly on the 2026 clinical-trial record and what its design can establish.
What Is the CuHeal Trial?
CuHeal is the acronym attached to ClinicalTrials.gov record NCT07437586. The official title describes a Phase 2, randomized, double-blind, vehicle-controlled, split-wound study of a topical GHK-Cu complex gel in standardized acute skin wounds in healthy adults. Hudson Biotech is listed as the sponsor, and Peking University Shenzhen Hospital is the recruiting location.
The record was first submitted on February 22, 2026, first posted on February 27, and lists an actual start date of February 2. Its status was verified in February 2026. These are registry facts, not outcome data. Registration documents what investigators plan to test; it does not tell readers whether the intervention worked.
Who is represented in the planned study?
The registry lists an estimated enrollment of 60 healthy adults ages 18 to 55, with a body-mass-index range of 18 to 30. It excludes several factors that could alter wound healing or study interpretation, including diabetes, peripheral vascular disease, immunodeficiency, abnormal scarring history, current nicotine use, and certain recent medications.
That controlled population improves experimental consistency, but it also limits generalization. Results in screened healthy adults with standardized wounds would not automatically predict findings in older adults, chronic wounds, diabetes-associated wounds, or other clinical populations.
How the Paired Split-Wound Design Works
Each participant receives two standardized punch-biopsy wounds on the same upper arm. One wound is randomized to the GHK-Cu study formulation and the other to the matching vehicle. Because both comparisons occur within one person, the design can reduce variation from age, genetics, baseline physiology, and other participant-level characteristics.
The registry labels the masking as quadruple: participant, care provider, investigator, and outcomes assessor. It also states that the two gels are intended to be identical in appearance, packaging, and labeling, with blinded assessors reviewing standardized photographs. Masking is valuable because expectations can influence care, symptom reports, and assessment. Its success still needs to be evaluated when results are reported.
Why “vehicle controlled” is important
A gel base can affect moisture, contact, and local wound conditions. Comparing the active formulation with its vehicle is therefore more informative than comparing it with no formulation at all. If completed data show a difference, the design is intended to isolate the contribution associated with adding GHK-Cu to the otherwise matched base.
What Is CuHeal Measuring?
The primary endpoint: time to complete re-epithelialization
The prespecified primary outcome is the number of days until complete re-epithelialization of each wound within a 21-day window. The registry defines completion as 100% epithelial coverage without drainage, confirmed by blinded clinical assessment and standardized photography.
Re-epithelialization is the restoration of epithelial coverage across the wound surface. It is narrower than the entire wound-healing process, which also includes inflammation, matrix formation, remodeling, and scar evolution. A change in this endpoint would not by itself answer every question about long-term tissue quality.
Secondary outcomes add context
Listed secondary measures include wound-area reduction, the proportion of wounds healed, suspected or confirmed infection, participant-reported pain, local tolerability, adverse events, and scar quality using POSAS at 12 weeks. These measures can help interpret whether a primary-endpoint difference is accompanied by changes in other clinically relevant observations.
Secondary endpoints should remain secondary in interpretation. Their time frames differ, and a result in one measure does not guarantee a result in another. The final analysis plan, missing data, confidence intervals, and multiplicity handling will matter once data are available.
Evidence Matrix: What Each Source Can Support
| Source | Material and model | What it supports | What it cannot establish |
|---|---|---|---|
| NCT07437586 registry | Planned paired Phase 2 study in 60 healthy adults | Status, design, population, endpoints, sponsor, location, and estimated dates | Efficacy, completed enrollment, safety conclusions, or results |
| PMID 29986520 | 2018 narrative review of GHK/GHK-Cu literature | Historical context for cell, animal, gene-expression, and cosmetic research | A new randomized wound-healing outcome or an unbiased effect estimate |
| PMID 26236730 | 2015 narrative review focused on skin-regeneration pathways | Context for matrix regulation, fibroblast signaling, animal wounds, and IL-6 experiments | Clinical proof, a Phase 2 result, or direct comparison with CuHeal |
This source matrix applies the same rule to every claim: registry data describe the planned experiment, while reviews summarize older evidence. Neither category can be rewritten as a completed 2026 efficacy result.
What Earlier Research Adds—and Where It Stops
Cell and signaling studies
A 2015 review in BioMed Research International describes experiments in which GHK or GHK-Cu altered collagen and glycosaminoglycan synthesis, matrix-metalloproteinase activity, fibroblast behavior, and inflammatory signaling. It also summarizes a normal-human-dermal-fibroblast experiment in which copper complexes of GHK reduced TNF-alpha-induced IL-6 secretion.
These experiments identify plausible pathways and measurable laboratory responses. They do not show that a formulated gel changes healing time in people. Cell cultures lack the full vascular, immune, mechanical, microbial, and behavioral environment of a human wound.
Animal wound models
The 2015 and 2018 reviews summarize rabbit, rat, mouse, pig, and dog research involving GHK-related materials and wound models. Reported observations include changes in contraction, granulation tissue, collagen, antioxidant enzymes, blood-vessel formation, and inflammatory markers under specific experimental conditions.
Animal studies can test biological plausibility and guide design. Species differences, wound type, material formulation, and experimental conditions prevent direct translation into a human effect estimate. CuHeal exists precisely because a controlled human question remains unresolved.
Older human cosmetic studies
The reviews also describe human cosmetic studies involving GHK-Cu-containing creams and appearance-related endpoints such as skin density, thickness, lines, and photodamage. Those studies differ from CuHeal in population, formulation, tissue condition, outcome, and purpose. Cosmetic appearance findings should not be treated as acute-wound evidence.
Why the Trial Is Not Yet an Answer
ClinicalTrials.gov currently marks NCT07437586 as recruiting and reports no posted results. Estimated primary completion is February 14, 2027, while estimated study completion is March 17, 2028. Those dates can change. A registration alone cannot reveal whether enrollment reached its target, masking held, groups differed, adverse events occurred, or the primary analysis favored either wound assignment.
A credible future interpretation will need the participant flow, protocol deviations, missing-data handling, numerical effect size, uncertainty interval, prespecified statistical analysis, adverse-event table, and complete secondary-outcome reporting. A status update or headline without those details would be insufficient.
How to Read the Eventual Results
| Question | Why it matters |
|---|---|
| Did the study meet the prespecified primary endpoint? | Prevents selective focus on a more favorable secondary measure. |
| How large was the within-participant difference? | Statistical significance alone does not show practical magnitude. |
| What were the confidence intervals? | They show the precision and range compatible with the data. |
| Were all randomized wounds included in analysis? | Attrition and exclusions can distort paired comparisons. |
| Did masking remain credible? | Visible or sensory differences could influence assessment. |
| Were adverse events and local tolerability fully reported? | Benefit and risk observations must be evaluated together. |
| Did scar and symptom outcomes align with re-epithelialization? | A faster primary endpoint may not imply improvement in every later outcome. |
Key Terms and Definitions
- Phase 2
- A development stage that typically explores biological or clinical activity and continues safety evaluation in a defined population. It is not proof of success.
- Randomization
- Assignment by chance, used here at the wound level to reduce systematic allocation bias.
- Vehicle
- The base formulation without the active study material.
- Masking
- Keeping assigned conditions hidden from specified participants or study personnel to reduce expectation and assessment bias.
- Re-epithelialization
- Restoration of epithelial coverage over a wound surface.
- POSAS
- The Patient and Observer Scar Assessment Scale, listed as a 12-week secondary outcome.
- Estimated enrollment
- A planned recruitment target, not a completed participant count.
Frequently Asked Questions About the GHK-Cu CuHeal Trial
Is there a registered clinical trial studying GHK-Cu?
Yes. ClinicalTrials.gov lists NCT07437586, the CuHeal study, as a recruiting Phase 2 trial of a GHK-Cu gel in standardized acute skin wounds.
What is the CuHeal study testing?
It is testing whether wounds assigned to the GHK-Cu study gel reach complete re-epithelialization sooner than paired wounds assigned to a matching vehicle gel.
What is re-epithelialization?
Re-epithelialization is the restoration of epithelial coverage over a wound surface. The registry defines completion as full epithelial coverage without drainage, confirmed by blinded assessment and standardized photography.
Why does the study use two wounds per participant?
The paired design lets each participant serve as their own comparison. That can reduce variation caused by participant-level factors, although it does not remove every source of bias or uncertainty.
How many participants does CuHeal plan to enroll?
The registry lists an estimated enrollment of 60 healthy adults ages 18 to 55. Estimated enrollment is a target, not proof that 60 participants have completed the study.
Does the CuHeal trial have results yet?
No. The ClinicalTrials.gov record currently reports no posted results and lists the study as recruiting, with estimated primary completion in February 2027.
What evidence existed before this Phase 2 trial?
The reviewed literature includes cell-culture findings, animal wound models, mechanistic research, and older cosmetic studies. These sources provide context but cannot substitute for pending randomized wound-healing results.
Does a Phase 2 trial prove that GHK-Cu works?
No. A Phase 2 designation describes a development stage and study design. Conclusions depend on completed data, prespecified analyses, effect size, uncertainty, safety findings, and independent review.
What is a vehicle-controlled trial?
A vehicle-controlled trial compares the study formulation with the same base formulation without the active study material. This helps isolate whether observed differences are associated with the added material.
What is POSAS?
POSAS is the Patient and Observer Scar Assessment Scale. CuHeal lists it as a secondary scar-quality measure at 12 weeks, not as the primary endpoint.
Is GHK-Cu the same as TB-500 or BPC-157?
No. GHK-Cu is a copper-binding tripeptide complex. TB-500 and BPC-157 refer to different research materials with different identities and evidence bases.
Does this article provide human-use guidance?
No. This is research education only. It provides no dosing, route, administration, treatment, efficacy, or safety instructions, and BioPharma materials are not intended for human or veterinary use.
Sources
- ClinicalTrials.gov: Topical GHK-Cu Gel for Acute Skin Wound Healing (CuHeal), NCT07437586. Registry record; recruiting; no results posted.
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018. PMID 29986520. Narrative review.
- GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015. PMID 26236730. Narrative review.
GHK-Cu Research Material at BioPharma
Qualified laboratories can review BioPharma GHK-Cu 50mg research material, compare the broader research peptides catalog, or consult BioPharma’s certificate-of-analysis guide. Catalog availability is separate from the CuHeal study formulation and does not imply a clinical indication, protocol, dose, route, treatment, safety profile, or expected outcome.
Research disclaimer: For research and laboratory use only. Not intended for human or veterinary use. This article does not constitute medical advice. BioPharma does not provide dosing, route, administration, treatment, efficacy, or safety guidance.
